BiomX Names Michael Oster as Chief Executive Officer, David Rokach Chief Financial Officer to Support Next Phase of Growth

BiomX (NYSE American: PHGE) announced on March 9, 2026 the appointment of Michael Oster as Chief Executive Officer and David Rokach as Chief Financial Officer to support the company’s next growth phase.

Rhea-AI Summary

BiomX (NYSE American: PHGE) announced on March 9, 2026 the appointment of Michael Oster as Chief Executive Officer and David Rokach as Chief Financial Officer to support the company’s next growth phase. Both executives bring senior experience in M&A, corporate strategy, finance, and capital markets.

BiomX is a clinical-stage company developing natural and engineered phage therapies targeting harmful bacteria in chronic diseases; the new leaders will focus on execution, capital strategy, and investor engagement.

Positive

• Appointed Michael Oster as CEO on March 9, 2026
• Appointed David Rokach as CFO with >20 years of finance experience
• Leadership brings experience in M&A, capital markets, and investor engagement

Argus Mar 9 session

+8.96% close to close Open Argus

Details

News Market Reaction – PHGE

On Mar 9, the day this news came out, PHGE closed 8.96% above the previous close.

Data tracked by StockTitan Argus for the Mar 9 session.

Market Context

On Mar 9, the day this news came out, the stock closed 9.0% above the previous close. A strong posit...

Analysis

On Mar 9, the day this news came out, the stock closed 9.0% above the previous close. A strong positive reaction aligns with the market’s focus on leadership credibility after recent program setbacks, governance turnover, and capital structure changes. Prior news often led to declines, except for a notable spike following a January trading-activity statement. The presence of an effective shelf registering 5,310,933 shares and Series Y preferred with a 15% dividend could still weigh on sustainability if resale or conversions add meaningful supply.

Key Figures

Alon USA revenue: $8 billion

Alon USA revenue

$8 billion

Revenue level at Alon USA Energy during Oster’s M&A leadership period

Historical Context

5 past events · Latest: Jan 27

5 events

1. Jan 27

   Trading activity statement

   24h Move

   +69.5%

   Company said no undisclosed developments despite unusual stock trading activity.

2. Dec 29

   Capital raise

   24h Move

   +3.6%

   Announced $3.0M private placement to support BX011 and strategic evaluation.

3. Dec 08

   Trial discontinued

   24h Move

   -36.9%

   Discontinued BX004 Phase 2b after high adverse events and began cost cuts.

4. Nov 25

   Trial update

   24h Move

   -18.7%

   FDA device review and dosing adjustments delayed BX004 Phase 2b topline data.

5. Nov 14

   Reverse split

   24h Move

   -15.9%

   Announced 1-for-19 reverse split, sharply reducing outstanding common shares.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Seasoned financial leaders join BiomX to support strategic execution and advancement of the company

DOVER, Del. and NESS ZIONA, Israel, March 9, 2026 /PRNewswire/ -- BiomX Inc. (NYSE American: PHGE), a clinical-stage company developing natural and engineered phage therapies designed to target and destroy harmful bacteria in chronic diseases, today announced the appointment of Michael Oster as Chief Executive Officer and David Rokach as Chief Financial Officer.

Oster brings extensive experience in corporate strategy, mergers and acquisitions, and operational leadership across capital-intensive industries including energy, infrastructure, and industrial sectors. Throughout his career, he has led complex transactions and built operational platforms designed to support long-term shareholder value. Currently, Oster serves as CEO and board member of Saffron Tech Ltd., an agritech company focused on innovative saffron cultivation technologies, as well as a member of the Board of Directors of BladeRanger Ltd., a publicly traded Israeli innovator in advanced drone payload systems for defense, homeland security, and solar applications.

Earlier in his career, Oster served as Senior Vice President of Mergers and Acquisitions at Alon USA Energy, Inc., where he led numerous strategic transactions during the company's growth as a publicly traded energy company with approximately $8 billion in revenue.

David Rokach joins the company as Chief Financial Officer. He brings more than two decades of experience in finance, investment management, and corporate leadership. Rokach will oversee BiomX's financial strategy, capital markets activities, accounting, and investor relations. Rokach serves as a member of the board of directors of T3 Defense Inc. since 2024. He previously served as Chief Executive Officer of Newcom Finance and Granit Investment Company, and has advised corporations and hedge funds on strategic and financial initiatives.

"The company is entering an important phase as we evaluate business opportunities and continue executing on our development strategy," said Michael Oster, CEO of BiomX. "I look forward to working closely with our team to advance our programs, maintain disciplined execution, and deliver meaningful milestones that support long-term value for our shareholders."

"My focus will be on supporting the company's strategy with disciplined financial management and a capital approach aligned with our priorities," said David Rokach, CFO of BiomX. "I look forward to working with the leadership team to strengthen engagement with the investment community and help position BiomX for sustained progress."

About BiomX

BiomX is a clinical-stage company leading the development of natural and engineered phage cocktails and personalized phage treatments designed to target and destroy harmful bacteria for the treatment of chronic diseases with substantial unmet needs. BiomX discovers and validates proprietary bacterial targets and applies its BOLT ("BacteriOphage Lead to Treatment") platform to customize phage compositions against these targets. For more information, please visit www.biomx.com, the content of which does not form a part of this press release.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding BiomX's strategy, the advancement of its clinical programs, future development milestones, financial strategy, and potential long-term growth. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements. These risks include, but are not limited to, risks related to the Company's clinical development programs, the timing and outcome of clinical trials, regulatory approvals, the Company's ability to obtain additional funding, and other risks described in BiomX's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent filings. BiomX undertakes no obligation to update or revise any forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.

Contact:

Yair Ohayon
Head of Marcomm & IR
info@biomx.com

View original content:https://www.prnewswire.com/news-releases/biomx-names-michael-oster-as-chief-executive-officer-david-rokach-chief-financial-officer-to-support-next-phase-of-growth-302708067.html

SOURCE Biomx Ltd.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is the new CEO of BiomX (PHGE) and when was he appointed?

The new CEO is Michael Oster, appointed on March 9, 2026. According to the company, Oster brings experience in corporate strategy, M&A, and operational leadership across capital-intensive industries, and will lead execution of BiomX’s development and growth priorities.

What are CFO David Rokach’s responsibilities at BiomX (PHGE)?

David Rokach will serve as Chief Financial Officer overseeing financial strategy, capital markets, accounting, and investor relations. According to the company, Rokach brings more than two decades of finance and investment experience to support disciplined capital management.

How do the new executives affect BiomX’s clinical-stage programs (PHGE)?

The hires aim to strengthen execution and financial oversight for BiomX’s clinical programs. According to the company, leadership will focus on advancing programs, executing development strategy, and delivering milestones to support long-term shareholder value.

Does BiomX (PHGE) expect changes to its capital strategy after the appointments?

BiomX indicated a renewed focus on disciplined capital management and investor engagement. According to the company, CFO Rokach will align the capital approach with corporate priorities to support sustained progress and access to capital markets.

What relevant experience does Michael Oster bring to BiomX (PHGE)?

Oster brings experience in corporate strategy, mergers and acquisitions, and operational leadership across energy and infrastructure sectors. According to the company, his background includes CEO roles and board positions supporting complex transactions and operational scaling.

Will the leadership changes at BiomX (PHGE) change the company’s public strategy?

The company signaled continued execution of its development strategy under new leadership. According to the company, the focus will remain on advancing programs while strengthening financial discipline and engagement with the investment community.